Blog — NephJC

nejm

REGENCY: A B-Cell Super Destroyer in Lupus

REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

FLOW - El Resumen Visual

¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!

Del monstruo de Gila al estudio FLOW.

Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.

Optimizing “Sparse” Treatments for FSGS

Optimizing “Sparse” Treatments for FSGS

This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?

ADVOR TRIAL - Can the addition of a little buddy make a big difference ?

ADVOR TRIAL - Can the addition of a little buddy make a big difference ?

This week, we will discuss The ADVOR trial, possibly the only randomized, placebo controlled trial of sequential nephron blockade ever. Could the use of acetazolamide in acute decompensated heart failure make a difference?